SCHEMBL3268752

SCHEMBL3268752

Cc1ccc2cc(Cl)ccc2c1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.46
POLB P06746 1/20 0.43
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALOX15 P16050 1/20 0.40
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
CYP2A6 P11509 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK7 P50613 1/20 0.36
CCNH P51946 1/20 0.36
CCNA1 P78396 1/20 0.36
TYMS P04818 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273914 0.87 LMNA (0.43) ERN1POLBTP53SMN1; SMN2ALOX15
SCHEMBL6820167 0.81 TDP1 (0.44) ERN1TP53ALOX15TDP1CYP2A6
SCHEMBL812303 0.81 LMNA (0.53) ERN1LMNATDP1CYP2A6ALDH1A1
SCHEMBL3267347 0.79 ERN1 (0.47) ERN1ALOX15TDP1CYP2A6TYMS
SCHEMBL9446315 0.79 ERN1 (0.65) ERN1
SCHEMBL3268890 0.79 ERN1 (0.52) ERN1LMNACYP2A6TYMSALDH1A1
SCHEMBL10488182 0.75 CYP2A6 (0.45) ERN1SMN1; SMN2TDP1CYP2A6ALDH1A1
SCHEMBL11057827 0.75 POLB (0.46) POLBTP53SMN1; SMN2LMNACYP3A4
SCHEMBL11760407 0.73 ERN1 (0.42) ERN1POLBSMN1; SMN2TDP1MAPT
SCHEMBL13639879 0.73 ERN1 (0.79) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
CN-101300244-A Novel cercosporamide derivative DAIICHI SANKYO CO LTD (JP) 2008-11-05 CN disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 ERN1 337/4885POLB 4801/4885TP53 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.